02162.HK
Keymed Biosciences Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 67.05
+0.22%Year over year
Reported trailing growth
- Revenue
- -5.7%
- EBITDA
- -92.3%
- EBIT
- -76.9%
- EPS
- +383.7%
- Free cash flow
- -0.3%
- Operating cash flow
- +1.3%
Forward estimates
Based on analyst estimates
- Revenue
- +110.5%
- EBITDA
- +79.8%
- EPS
- —
Three-year CAGR
- Revenue
- +91.1%
- EBITDA
- +8.6%
- EBIT
- +5.4%
- Net income
- +1.2%
- EPS
- +5.6%
- Free cash flow
- -4.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026